移植治疗在儿童与青少年1型糖尿病治疗中的应用进展

doi:10.12372/jcp.2022.22e0253

Abstract

Abstract:

Prevalence of type 1 diabetes in children and adolescents rises in decades of years. Medication could keep the serum level of glucose in a reasonable range rather than cure the disease. Transplantation, mainly islet transplantation, stem cell transplantation and pancreas transplantation, has attracted more attention for the possibility of curing type 1 diabetes. Rejection, islet inflammation and apoptosis hinder a successful transplantation, which may be relieved by carbon monoxide or regulatory T cell therapies. Most of studies about transplantation treatment for type 1 diabetes were on animals or adults, with few on children and adolescents. Furthermore, fecal microbiota transplantation could halt progression of human new-onset type 1 diabetes, which could be an adjuvant therapy in future days.

Key words: transplantation, child, adolescent, type 1 diabetes

CHEN Yao, WANG Xiumin. Advances in transplantation therapy in the treatment of type 1 diabetes in children and adolescents[J].Journal of Clinical Pediatrics, 2022, 40(5): 334-338.

References 20

[1]	American Diabetes Association Professional Practice Committee, American Diabetes Association Professional Practice Committee, Draznin B, et al. Classification and diagnosis of diabetes: standards of medical care in diabetes-2022[J]. Diabetes Care, 2022, 45(Suppl 1): S17-S38. doi: 10.2337/dc22-S002
[2]	Wherrett DK, Chiang JL, Delamater AM, et al. Defining pathways for development of disease-modifying therapies in children with type 1 diabetes: a consensus report[J]. Diabetes Care, 2015, 38(10): 1975-1985. doi: 10.2337/dc15-1429 pmid: 26404927
[3]	Chiang JL, Maahs DM, Garvey KC, et al. Type 1 diabetes in children and adolescents: A position statement by the American diabetes association[J]. Diabetes Care, 2018, 41(9): 2026-2044. doi: 10.2337/dci18-0023 pmid: 30093549
[4]	Chamberlain JJ, Kalyani RR, Leal S, et al. Treatment of type 1 diabetes: Synopsis of the 2017 American diabetes association standards of medical care in diabetes[J]. Ann Intern Med, 2017, 167(7): 493-498. doi: 10.7326/M17-1259 pmid: 28892816
[5]	Gamble A, Pepper AR, Bruni A, et al. The journey of islet cell transplantation and future development[J]. Islets, 2018, 10(2): 80-94. doi: 10.1080/19382014.2018.1428511
[6]	Chetboun M, Jannin A, Kerr-Conte J, et al. 1921-2021: From insulin discovery to islet transplantation in type 1 diabetes[J]. Ann Endocrinol (Paris), 2021, 82(2): 74-77. doi: 10.1016/j.ando.2021.03.006
[7]	Brooks AM, Oram R, Home P, et al. Demonstration of an intrinsic relationship between endogenous C-peptide concentration and determinants of glycemic control in type 1 diabetes following islet transplantation[J]. Diabetes Care, 2015, 38(1): 105-112. doi: 10.2337/dc14-1656
[8]	Vantyghem MC, Raverdy V, Balavoine AS, et al. Continuous glucose monitoring after islet transplantation in type 1 diabetes: an excellent graft function (β-score greater than 7) Is required to abrogate hyperglycemia, whereas a minimal function is necessary to suppress severe hypoglycemia (β-score greater than 3)[J]. J Clin Endocrinol Metab, 2012, 97(11): E2078- E2083.
[9]	Shapiro AM, Pokrywczynska M, Ricordi C. Clinical pancreatic islet transplantation[J]. Nat Rev Endocrinol, 2017, 13(5): 268-277. doi: 10.1038/nrendo.2016.178 pmid: 27834384
[10]	Dugbartey GJ. Carbon monoxide in pancreatic islet transplantation: A new therapeutic alternative to patients with severe type 1 diabetes mellitus[J]. Front Pharmacol, 2021, 12: 750816. doi: 10.3389/fphar.2021.750816
[11]	Marfil-Garza BA, Hefler J, Bermudez De Leon M, et al. Progress in translational regulatory T cell therapies for type 1 diabetes and islet transplantation[J]. Endocr Rev, 2021, 42(2): 198-218. doi: 10.1210/endrev/bnaa028 pmid: 33247733
[12]	Tootee A, Nikbin B, Ghahary A, et al. Assessment of immune-alternations and their correlations with therapeutic outcomes of transplantation of autologous Mesenchymal and Allogenic fetal stem cells in patients with type 1 diabetes: a study protocol[J]. J Diabetes Metab Disord, 2021, 20(1): 1067-1073. doi: 10.1007/s40200-020-00716-9
[13]	Lu J, Shen SM, Ling Q, et al. One repeated transplantation of allogeneic umbilical cord mesenchymal stromal cells in type 1 diabetes: an open parallel controlled clinical study[J]. Stem Cell Res Ther, 2021, 12(1): 340. doi: 10.1186/s13287-021-02417-3
[14]	Voltarelli JC, Couri CE, Stracieri AB, et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus[J]. JAMA, 2007, 297(14): 1568-1576. doi: 10.1001/jama.297.14.1568 pmid: 17426276
[15]	Malmegrim KC, de Azevedo JT, Arruda LC, et al. Immunological balance is associated with clinical outcome after autologous hematopoietic stem cell transplantation in type 1 diabetes[J]. Front Immunol, 2017, 8:167. doi: 10.3389/fimmu.2017.00167 pmid: 28275376
[16]	Lindahl JP, Hartmann A, Horneland R, et al. Improved patient survival with simultaneous pancreas and kidney transplantation in recipients with diabetic end-stage renal disease[J]. Diabetologia, 2013, 56(6): 1364-1371. doi: 10.1007/s00125-013-2888-y pmid: 23549518
[17]	Chudek J, Kolonko A, Ziaja J, et al. Beneficial effect of successful simultaneous pancreas-kidney transplantation on plasma profile of metalloproteinases in type 1 diabetes mellitus patients[J]. J Clin Med, 2021, 10(17): 3800. doi: 10.3390/jcm10173800
[18]	Cho JA, Chinnapen DJF. Targeting friend and foe: Emerging therapeutics in the age of gut microbiome and disease[J]. J Microbiol, 2018, 56(3): 183-188. doi: 10.1007/s12275-018-8037-z
[19]	Mariño E, Richards JL, McLeod KH, et al. Gut microbial metabolites limit the frequency of autoimmune T cells and protect against type 1 diabetes[J]. Nat Immunol, 2017, 18(5): 552-562. doi: 10.1038/ni.3713
[20]	de Groot P, Nikolic T, Pellegrini S, et al. Faecal microbiota transplantation halts progression of human new-onset type 1 diabetes in a randomised controlled trial[J]. Gut, 2021, 70(1): 92-105. doi: 10.1136/gutjnl-2020-322630

Advances in transplantation therapy in the treatment of type 1 diabetes in children and adolescents

RichHTML

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

References 20

Related Articles 15

Metrics

Comments

Recommended 0

[1]	ZOU Liping. Childhood encephalopathy: a group of diseases associated with various diseases [J]. Journal of Clinical Pediatrics, 2023, 41(9): 641-643.
[2]	ZHANG Weihua, ZOU Liping, REN Haitao, GUAN Hongzhi. Beware of the pitfalls in diagnosis and treatment of autoimmune encephalitis in children [J]. Journal of Clinical Pediatrics, 2023, 41(9): 644-649.
[3]	HOU Chi, CHEN Wenxiong, LIAO Yinting, WU Wenxiao, TIAN Yang, ZHU Haixia, PENG Bingwei, ZENG Yiru, WU Wenlin, CHEN Zongzong, LI Xiaojing. Clinical analysis of autoimmune glial fibrillary acidic protein astrocytopathy in children [J]. Journal of Clinical Pediatrics, 2023, 41(9): 656-660.
[4]	YANG Yating, CAI Yuehao, FANG Qiong, CHEN Lang, CHEN Qiaobin, LIN Zhi, WU Feifei, LIN Meng. Clinical analysis of idiopathic and symptomatic occipital lobe epilepsy in children [J]. Journal of Clinical Pediatrics, 2023, 41(9): 668-673.
[5]	HOU Ruolin, WU Jing, LI Ling. Pediatric autoimmune encephalitis with brain MRI showing meningeal thickening and enhancement [J]. Journal of Clinical Pediatrics, 2023, 41(9): 674-679.
[6]	WU Yuefang, SUN Yanling, WU Wanshui, DU Shuxu, LI Miao, SUN Liming. Analysis of prognostic factors and survival status of group 4 medulloblastoma in children [J]. Journal of Clinical Pediatrics, 2023, 41(9): 686-691.
[7]	SUN Juan, LI Haiying, JIA Peisheng, WANG Huaili. Clinical analysis of fulminant myocarditis in 12 children [J]. Journal of Clinical Pediatrics, 2023, 41(9): 692-696.
[8]	Reviewer: WANG Chenhui, Reviser: YANG Hui. Research progress on early screening and diagnosis of Crohn's disease in children [J]. Journal of Clinical Pediatrics, 2023, 41(9): 708-714.
[9]	SHEN Nan, DU Bailu. Strategies for the diagnosis, treatment, and management of invasive fungal infections in children with hematologic neoplasms [J]. Journal of Clinical Pediatrics, 2023, 41(8): 571-577.
[10]	XU Beixue, LIU Quanbo. Clinical analysis of 195 children with invasive pulmonary fungal infection [J]. Journal of Clinical Pediatrics, 2023, 41(8): 584-588.
[11]	CHEN Hongyu, LIU Zihao, WANG Heping, LIAO Cuijuan, LI Li, WANG Wenjian, LAI Jianwei. Role of nontypeable Haemophilus influenzae biofilms in chronic pulmonary infection in children [J]. Journal of Clinical Pediatrics, 2023, 41(8): 589-593.
[12]	KANG Lei, GUO Fang, LI Lifang, BAI Xinfeng, CHENG Caiyun, XU Meixian. Value of metagenomic next-generation sequencing in children with visceral leishmaniasis associated with hemolytic histiocytosis [J]. Journal of Clinical Pediatrics, 2023, 41(8): 594-598.
[13]	SUN Zhicai, LIU Yuling, LI Xiaolin, PAN Xiaofen. Clinical analysis of 15 children with primary nephrotic syndrome complicated with adrenal crisis [J]. Journal of Clinical Pediatrics, 2023, 41(8): 610-612.
[14]	WANG Hongxia, PAN Xiang, LU Jun. Report a case of α-ketoadipic aciduria caused by compound heterozygous variant of DHTKD1 gene [J]. Journal of Clinical Pediatrics, 2023, 41(8): 624-628.
[15]	XI Bixin, HU Qun, LIU Aiguo. Research advances of the bronchiolitis obliterans syndrome following allogeneic hematopoietic stem cell transplant in children [J]. Journal of Clinical Pediatrics, 2023, 41(8): 629-633.